Headlines about Novavax (NASDAQ:NVAX) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novavax earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.8158267161601 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Analyst’s Proposition on Symantec Corporation (SYMC), Novavax, Inc. (NVAX) – AppsforPCdaily (appsforpcdaily.com)
- Novavax, Inc. (NVAX) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Novavax, Inc. (NVAX) Stock Price stands 7.03% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Novavax: Catalysts Building Toward A Crescendo – Novavax, Inc … – Seeking Alpha (seekingalpha.com)
Novavax (NVAX) traded up 1.79% during mid-day trading on Tuesday, reaching $1.14. The company had a trading volume of 4,732,636 shares. Novavax has a one year low of $0.73 and a one year high of $2.47. The firm’s market capitalization is $330.49 million. The firm’s 50-day moving average is $1.05 and its 200-day moving average is $1.09.
Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.15 million. During the same quarter last year, the business posted ($0.29) EPS. The business’s revenue was up 168.0% on a year-over-year basis. On average, equities research analysts anticipate that Novavax will post ($0.62) earnings per share for the current fiscal year.
A number of analysts have recently commented on the company. BidaskClub raised Novavax from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Zacks Investment Research raised Novavax from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Wednesday, August 16th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $1.50 price target on shares of Novavax in a research note on Wednesday, July 26th. Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target for the company in a research note on Wednesday, August 9th. Finally, Chardan Capital reaffirmed a “neutral” rating and issued a $1.50 price target on shares of Novavax in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.05.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/09/19/novavax-nvax-receiving-somewhat-favorable-news-coverage-study-finds.html.
In other Novavax news, Director James F. Young sold 175,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.00% of the company’s stock.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.